CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
C	ETV6::NTRK3	Fusion	Oncogenic	Supports	Oncogenicity	Congenital Fibrosarcoma		Knezevich et al., 1998
D	ETV6::NTRK3	Fusion	Oncogenic	Supports	Oncogenicity	Breast Secretory Carcinoma		Tognon et al., 2002
D	TP53	R175H	Functional	Supports	Dominant Negative			Marutani et al., 1999
D	TP53	R156H	Functional	Supports	Dominant Negative			Marutani et al., 1999
D	TP53	H178P	Functional	Supports	Dominant Negative			Marutani et al., 1999
D	TP53	H179R	Functional	Supports	Dominant Negative			Marutani et al., 1999
D	TP53	R181P	Functional	Supports	Dominant Negative			Marutani et al., 1999
D	TP53	G245S	Functional	Supports	Dominant Negative			Marutani et al., 1999
D	TP53	R249S	Functional	Supports	Dominant Negative			Marutani et al., 1999
D	TP53	E68G	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	L111R	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	H115Y	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	C124R	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	C135W	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	L139N	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	P152L	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	R158G	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	R158H	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	G266V	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	G266E	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	F270S	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	V272G	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	EML4::NTRK3	Fusion	Oncogenic	Supports	Oncogenicity	Colon Cancer		Kloosterman et al., 2017
C	ETV6::NTRK3	Fusion	Predictive	Supports	Sensitivity/Response	Congenital Fibrosarcoma	Larotrectinib	Bielack et al., 2019
D	FGFR3	G697C	Oncogenic	Does Not Support	Oncogenicity	Cancer		Patani et al., 2016
B	ETV6::NTRK3	Fusion	Diagnostic	Supports	Positive	Congenital Mesoblastic Nephroma		Vokuhl et al., 2018
B	BCOR	ITD	Diagnostic	Supports	Positive	Central Nervous System Tumor With BCOR Internal Tandem Duplication		Ferris et al., 2020
C	EGFR::PURB	Fusion	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Erlotinib	Konduri et al., 2016
C	EGFR::RAD51	Fusion	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Osimertinib	Copia Sperandio et al., 2022
C	KIF5B::EGFR	Fusion	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	Wang et al., 2021
D	SRSF2	P95L	Predictive	Supports	Sensitivity/Response	Myeloid Neoplasm	CTX-712	Yoda et al., 2021
D	SRSF2	P95H	Predictive	Supports	Sensitivity/Response	Myeloid Neoplasm	CTX-712	Yoda et al., 2021
B	H3-3A	K28M	Diagnostic	Supports	Positive	Brain Glioblastoma Multiforme		Wu et al., 2012
D	SMARCA2	R1159Q	Functional	Supports	Neomorphic			Gao et al., 2019
D	SMARCA2	K755R	Functional	Supports	Neomorphic			Gao et al., 2019
D	RAF1	R391W	Functional	Supports	Gain of Function			Atefi et al., 2016
D	FLT3	D835Y	Predictive	Supports	Sensitivity/Response	Cancer	FLT3 Tyrosine Kinase Inhibitor TTT-3002,Midostaurin,Lestaurtinib,Crenolanib	Nguyen et al., 2017
D	FLT3	D835Y	Predictive	Does Not Support	Sensitivity/Response	Cancer	Ponatinib,AG1295,AGS324,Linifanib,Quizartinib,Sunitinib,Sorafenib,R406,KW2449	Nguyen et al., 2017
D	FLT3	Overexpression AND FLT3LG Expression	Predictive	Does Not Support	Sensitivity/Response	Cancer	Crenolanib,R406,AG1295	Nguyen et al., 2017
D	FLT3	D593del	Predictive	Supports	Sensitivity/Response	Cancer	FLT3 Tyrosine Kinase Inhibitor TTT-3002,Midostaurin,Lestaurtinib,Crenolanib	Nguyen et al., 2017
C	EML4::NTRK3	Fusion	Predictive	Supports	Sensitivity/Response	High Grade Glioma	Larotrectinib	Waters et al., 2021
C	EML4::ALK	Fusion AND ALK I1171N AND ALK L1196M	Predictive	Supports	Sensitivity/Response	Malignant Pleural Mesothelioma	Lorlatinib	Hu et al., 2020
C	EML4::ALK	Fusion AND ALK G1202R AND ALK I1171N AND ALK L1196M	Predictive	Supports	Resistance	Malignant Pleural Mesothelioma	Lorlatinib	Hu et al., 2020
A	v::ALK	Fusion	Predictive	Supports	Sensitivity/Response	Inflammatory Myofibroblastic Tumor	Crizotinib	Gambacorti-Passerini et al., 2018
D	EGFR	S645C	Oncogenic	Supports	Oncogenicity	Lung Cancer		Berger et al., 2016
D	EGFR	K754E	Oncogenic	Supports	Oncogenicity	Lung Cancer		Berger et al., 2016
D	ARAF	S214F	Oncogenic	Supports	Oncogenicity	Lung Cancer		Berger et al., 2016
D	ARAF	S214C	Oncogenic	Supports	Oncogenicity	Lung Cancer		Berger et al., 2016
D	ARAF	V145L	Oncogenic	Does Not Support	Oncogenicity	Lung Cancer		Berger et al., 2016
D	GNA11	R183C	Functional	Supports	Gain of Function			Thomas et al., 2016

Page 62 of 96

Previous Next